Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 5/20 | 0.46 |
| ▸ | ADH1A | P07327 | 5/20 | 0.46 |
| ▸ | ADH7 | P40394 | 4/20 | 0.46 |
| ▸ | ADH1C | P00326 | 4/20 | 0.46 |
| ▸ | ADH4 | P08319 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8186479 | 0.78 | ADH1B (0.54) | ADH1BADH1AADH7ADH1CADH4 | |
| SCHEMBL19935801 | 0.77 | EPHX1 (0.41) | EPHX1 | |
| SCHEMBL11153834 | 0.76 | ADH1B (0.56) | ADH1BADH1AADH7ADH1CADH4 | |
| SCHEMBL14937478 | 0.76 | ADH1B (0.56) | ADH1BADH1AADH7ADH1CADH4 | |
| SCHEMBL11568445 | 0.76 | ADH1B (0.56) | ADH1BADH1AADH7ADH1CADH4 | |
| SCHEMBL11354637 | 0.76 | ADH1B (0.56) | ADH1BADH1AADH7ADH1CADH4 | |
| SCHEMBL11569625 | 0.76 | ADH1B (0.56) | ADH1BADH1AADH7ADH1CADH4 | |
| SCHEMBL11413206 | 0.74 | ADH1B (0.50) | ADH1BADH1AADH7ADH1CADH4 | |
| SCHEMBL12519632 | 0.74 | ADH1B (0.50) | ADH1BADH1AADH7ADH1CADH4 | |
| SCHEMBL20821943 | 0.73 | ADH1B (0.37) | ADH1BADH1AADH7ADH1CADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011084993-A1 | POLYMERS PREPARED FROM MIXTURES OF MULTIFUNCTIONAL N-VINYLFORMAMIDE AND HYBRID REACTIVE N-VINYLFORMAMIDE CROSSLINKING MONOMER MOIETIES AND USES THEREOF | ISP INVESTMENTS INC. (US) | 2011-07-14 | — | — | WO | disclosed |